• Full life cycle business development (BD): - Negotiated and closed 3x out-licensing and co-development deals with top global pharma co's • Alliance Manage: 3x partnerships, including $1B+ biobucks multinational collaboration• Drove pipeline strategy: for autoimmune disease and oncology assets (mAbs, bispecifics and ADCs)• Corporate growth strategy: direct report to company President and head of US operationsAI/ML large molecule biotech startup

• Market research, product portfolio strategy, FP&A, and go to market strategy• Co-founder, board observer and now company advisorNanotein innovates, novel, best-in-class reagents for manufacturing better cell therapies

• Originally hired own (therapeutic asset) portfolio optimization and pipeline strategy- Analyzed, then through a combination of program cancelations and new program launches, 2x pipeline to 25 programs (CEO and Board goal), across therapeutic areas • Over time, I took ownership of (1) BD and Partnering, and (2) Alliance Management (managing 4x collaborations with partners across the US and Asia)• Contributed to: FP&A, program planning and budgeting, asset valuation and fundraising related work (operated as direct report to CEO)AI/ML small molecule pharma startup

Portfolio strategy & optimization: closed 2x pipeline programs + launched 15x others, to double Aria's pipeline to the organization's (CEO & BoD) defined goal of 25 total programs.Assessed existing programs & triaged ~10,000 disease (all major therapeutic areas), across ~30 different metrics, distributed across 7 major "buckets": • Commercial: unmet medical needs, current treatment paradigm, addressable market size (dx epidemiology and product pricing + GTN), target product profile (TPP) • Competitive landscape: approved drugs & those in clinical trial pipeline • Pre-Clinical R&D: required in vitro & in vivo experiments & models, required resources (time, cost and personnel) to advance to IND enablement• CMC: experimental, financial needs and timelines; GLP / cGMP• Clinical Development: trial design (trial size, patient populations, clinical end points, biomarkers/companion diagnostics), regulatory pathway, and cost + time estimates• Platform (AI), i.e. our (differentiating) core competency• IP strategy: e.g. composition of matter, methods of treatment, manufacturing and formulation patents, etc.Pipeline programs spanned multiple TA's including: oncology, inflammatory, metabolic, neuro, ophthalmology and orphan / rare disease

Part of EY-Parthenon's Life Sciences (LS) practice (i.e. Pharma, Biotech, Medtech & Private Equity)Focused on (1) Mergers & Acquisitions (M&A) Commercial Due Diligence, (2) Growth Strategy and (3) Commercial Strategy engagements (~10 engagements)

Interned in the Genentech's early stage (gRED) pipeline and portfolio planning (PPP). This group has three buckets of responsibility: (1) portfolio tracking, analysis and optimization / pruning for IND - Phase 2 assets, (2) decision & analysis support to (clinical trial) Molecule Teams, and (3) as in-house ad-hoc strategy & operations consultants. Worked across all three buckets.

I studied the biochemistry, molecular biology and cell biology of a highly prevalent, blinding, eye disease.

Boutique biopharma hedge fund. Performed scientific and clinical due diligence on the pipelines of three clinical-stage gene therapy companies. The aim was to help inform go / no-go equity investment decisions.(work was performed in parallel to earning my PhD)

Hexagon Bio is a VC backed, startup that uses data-science and synthetic biology to discover and build new therapeutics.Pipeline & Portfolio Strategy: performed primary & secondary market research, in order to prioritize Hexagon's highest value assets for further development. Helped assess ~600 molecules & biologic targets, across a large number of diseases & a wide variety of therapeutic areas.(work was performed in parallel to earning my PhD)

As part of a Bay Area Biotech Connection (BCBA) engagement I helped triage >600 potential therapeutic assets down to those of highest potential value to Hexagon.(work was performed in parallel to earning my PhD)

R&D of a non-viral gene therapy for an ocular autoimmune disease(work was performed in parallel to earning my PhD)

Development of an optogenetics-based, AAV viral gene therapy for treatment of chronic pain

Protein Biochemistry, Molecular Biology, X-ray Crystallography

R&D for a next-generation HIV diagnostic assays

prostate cancer research